Commercialization: Page 15

PharmaVoice Team/PharmaVoice

AI and Drug Discovery

Discovering and bringing new drugs to market is notoriously slow and costly for a reason. Science moves slowly because of the incredibly complex nature of human biology and the difficulty of sluggish recruitment of clinical trials. And in spite of greater investments in R&D by pharmaceutical ...
By Claire Bonaci • Oct. 1, 2020
PharmaVoice Team/PharmaVoice

The Accessibility of AI: Innovation at Your Fingertips

The availability of datasets keeps growing exponentially. With this we are witnessing an escalation of available new life-altering systems. Some of these tools are highly autonomous and can perform functions with little to no human intervention. Self-driving cars, rockets that land upright on dro...
By Max Divak • Oct. 1, 2020
PharmaVoice Team/PharmaVoice

AI-Driven Marketing

We have all seen those digital banners that are somehow related to what we’re looking at online and appear to follow us wherever we are. Don’t worry, there is nothing ominous at play and the government is not listening to our conversations through our devices. But this is not completely coinciden...
By J.P. Maranzani • Oct. 1, 2020
PharmaVoice Team/PharmaVoice

Leveraging AI to Slingshot Drugs from Lab to Market

The science of clinical development continually astounds even those of us intimately connected to it. We recognize that our overarching industry mandate — to develop and deliver safe and effective new therapies to fight and cure disease — must be continually informed by new thinking and tools if ...
By Malai Sankarasubbu • Oct. 1, 2020
PharmaVoice Team/PharmaVoice

The Salesforce of the Future

COVID-19 is fast-tracking the industry’s slow move from fewer in-person HCP visits to digital and virtual approaches. COVID-19 has driven vast changes in what healthcare providers need and value from pharma companies, and as a result, the industry is striving to develop new ways to engage with ph...
By Robin Robinson • Oct. 1, 2020
PharmaVoice Team/PharmaVoice

SHOWCASE: Patient Solutions: The Changing Face of Patient Engagement

Digital technologies are changing the healthcare landscape, creating opportunities for patient-support programs, patient monitoring and self-management. There is massive demand for patient-engagement solutions, with predictions that the market for such solutions will reach $30.36 billion by 2026....
By PharmaVoice Team • Oct. 1, 2020
PharmaVoice Team/PharmaVoice

Advancing Beyond the Traditional Patient Adherence Model

Delivering value in the era of empowered patients renders the one-size-fits-all patient services program obsolete. Not every treatment journey is consistently linear within a disease state because patients take different paths to medication adherence. For example, one patient may be compliant whe...
By Maria Kirsch • Oct. 1, 2020
PharmaVoice Team/PharmaVoice

Social Connection Is Possible in a Time of Physical Distancing

In this time of physical distancing, technology often seems like the go-to solution for helping people connect. However, data linking social media and depression, as well as research pointing to social divisiveness online, might give us pause. Recent survey results found most Americans believe th...
By Amrita Bhowmick • Oct. 1, 2020
PharmaVoice Team/PharmaVoice

Listening to the Patient for Better Outcomes

The aim of drug development is to improve patient outcomes. Historically, clinical research has been driven by researchers, with little or no input from patients, contributing to many of the challenges and inefficiencies we see in today’s clinical trials. Some of these challenges include low enro...
By Gretchen Goller • Oct. 1, 2020
PharmaVoice Team/PharmaVoice

Speak Out: The Power of Virtual Patient Simulation in CME

Simulation as we think of it today has been used in medical education since the 18th century,1 and has continued to evolve into realistic and medically accurate physical and digital solutions designed to allow learners to simulate a scenario-based encounter with a patient in a safe environment. V...
By Martin Warters • Oct. 1, 2020
PharmaVoice Team/PharmaVoice

Executive Perspective: AI With a Healthcare IQ: A Conversation with Lucas Glass and Andrew Ploszay

Since the term was first coined in 1955, “artificial intelligence" (AI) has led to significant advances across industries. From robotics to automobiles, to digital personal assistants, and even online shopping. In healthcare, AI has enabled many successes, but a few noteworthy failures have made ...
By Lucas Glass • Oct. 1, 2020
PharmaVoice Team/PharmaVoice

Letter from the Editor

What’s Next … Over the past several months, I, like everyone else, have wondered what’s next? What’s next if there’s not a vaccine approved soon? And, even if a vaccine is approved, how does that play out? What happens if there’s a next wave of COVID-19 that coincides with flu season? The what if...
By Taren Grom • Sept. 1, 2020
PharmaVoice Team/PharmaVoice

Upfront

Bristol Myers Squibb Commits $300 Million to Health Equity and Diversity and Inclusion Efforts Bristol Myers Squibb and the BMS Foundation are investing $300 million over the next five years to accelerate and sustain its diversity, equity, and inclusion efforts. Specifically, the company will foc...
By PharmaVoice Team • Sept. 1, 2020
PharmaVoice Team/PharmaVoice

HealthTech

Amwell Telehealth Use Swells During Pandemic Trend Watch: Technology Rises to the Challenges of COIVD-19 Amwell, a national telehealth company, which has been gaining app usage since the onslaught of COVID-19, has hired a new Chief Technology Officer Serkan Kutan. Mr. Kutan who comes from executi...
By PharmaVoice Team • Sept. 1, 2020
PharmaVoice Team/PharmaVoice

Artificial Intelligence

SOPHiA Genetics’ First Multimodal Approach to Predict COVID-19 Disease Evolution Trend Watch: AI Technology Helps in the Fight Against COVID-19 Health-tech company SOPHiA Genetics, specializing in data-driven medicine, has launched a first-of-its-kind multimodal solution to predict COVID-19 disea...
By PharmaVoice Team • Sept. 1, 2020
PharmaVoice Team/PharmaVoice

Last Word

Changing the Patient–Scientist Dialogue Paul Kidwell, Senior Public Relations/Patient Advocacy Consultant & Podcaster, for the life-sciences industry provides an insider’s view into the need for increased communication between patients and scientists. PV: What has been your experience in term...
By Paul Kidwell • Sept. 1, 2020
PharmaVoice Team/PharmaVoice

SHOWCASE: Big Data: Big is Better: The Importance of Data in Industry Advances

Big data is big business, and for the life-sciences and healthcare industries it’s playing an important role in informing everything from R&D to commercialization. With the growth of digital healthcare, it is estimated that the amount of data the industry is collecting is increasing by around...
By PharmaVoice Team • Sept. 1, 2020
PharmaVoice Team/PharmaVoice

Why Are We Settling for Mediocre Patient Services Programs?

Meet Dorothy: mother of twin 12-year-old girls who inherited her natural talent and love for tennis. Every weekend she coaches their junior team and analyzes each match on their way to get pizza. Dorothy thrives on the tennis court next to her girls; she feels energized and empowered. Monday morn...
By Maria Kirsch • Sept. 1, 2020
PharmaVoice Team/PharmaVoice

The Fabric of Data Cognizance

Effective data businesses have always been built on a foundation of individual honesty. Leaders faced with big decisions have been quick to listen to what their patients and employees tell them, but have also been slower to make judgments based on their gut instincts. The reason? EHR data just we...
By Angelo Campano • Sept. 1, 2020
PharmaVoice Team/PharmaVoice

Will Big Data Fundamentally Change Our Approach to the Next Pandemic?

Big Data…Hero at Large? The current COVID-19 pandemic has forced a rethink of drug discovery and healthcare management. Over the first half of 2020, we have seen an unprecedented speed of candidate drug evaluation for the treatment of COVID-19 and the development of vaccines directed against SARS...
By Iyiola Obayomi • Sept. 1, 2020
PharmaVoice Team/PharmaVoice

Turning Data into Storytelling

Beyond communications skills, creating a good data story requires research. Nobody wants to listen to a boring story. And for some, data can be boring, or at best, confusing. Telling an enthralling story takes a certain skill, and when the topic is a mound of eye-glazing data and analysis, it bec...
By Robin Robinson • Sept. 1, 2020
PharmaVoice Team/PharmaVoice

SHOWCASE: Digital Marketing: AI, VR, AR: A New Age of Digital Tools Changes the Game for Marketers

Whether it’s social media forums, internal digital platforms, AI-powered apps and chat bots, or augmented and virtual reality, the digital tools open to the pharma industry today are changing the face of marketing. More and more pharma companies are using digital tools to reach their audiences. A...
By PharmaVoice Team • Sept. 1, 2020
PharmaVoice Team/PharmaVoice

Leveraging Data and Machine Learning to Drive Brand Performance

There is no question that 2020 has been a year like none other, especially for those in the healthcare industry. For brand managers, that meant sales teams were grounded; budgets got frozen, or even cut in many cases; healthcare practitioners moved their offices virtual; and telehealth services j...
By Michelle Petroff • Sept. 1, 2020
PharmaVoice Team/PharmaVoice

Driving Digital Strategy Forward: Customer Engagement in COVID-19 and Beyond

The life-sciences industry is starting to find a new baseline, adapting to the abrupt remote digital pivot many organizations needed to make. While we acknowledge in recent years the industry has been on a path toward digital transformation, there’s no denying that the complications arising from ...
By IQVIA • Sept. 1, 2020
PharmaVoice Team/PharmaVoice

We're All Digital Natives

We’ve all heard the term “flatten the curve" to describe the efforts being made to curb infection rates of COVID-19, but today’s tumultuous climate is disrupting another curve — the adoption curve of digital health. In 2019, a survey revealed that two-thirds of patients were open to the idea of t...
By Christopher Jankoski • Sept. 1, 2020